Danimer Scientific Inc

Danimer Scientific — Q2 2023 Earnings Presentation

12 slides from Danimer Scientific's earnings presentation, Aug 8, 2023

  1. Slide 1: Second Quarter 2023 Earnings Presentation

    Second Quarter 2023 Earnings Presentation August 8, 2023

  2. Slide 2: Disclaimer and Forward-Looking Statements

    This presentation (“Presentation”) is for informational purposes only. This Presentation shall not constitute an offer to sell, or the solicitation of an offer to buy, any securities, nor shall there be any sale of securities in any states or jurisdictions in which such offer, solicitation or sale w

  3. Slide 3: Fast Facts

    FAST FACTS Founded in 2004 (went public in 2020) 480 patents & pending patent applications 15 partnerships with major brands and distributors 255 Teammates 2018 and 2020 recipient of PLASTICS Innovation in Bioplastics Award Locations in Georgia, Kentucky and New York Manufacturer of PHA Biopolymers

  4. Slide 4: Proprietary PHA-Based Resins with Disruptive Performance

    Certified biodegradable for home compost, natural soil and marine environments Highly-engineered to run on standard manufacturing equipment Indistinguishable from petroleum-based plastic to consumers at end-use Proprietary PHA-Based Resins with Disruptive Performance 1 Switch to PHA-based resin requ

  5. Slide 5: Recent Highlights

    Received acceptance of Part 2 application to Department of Energy Loan Guarantee Program; Invited to now take part in due diligence and term sheet negotiation for potential Department of Treasury Federal Financing for construction of Bainbridge, GA greenfield facility Customer launch of Nodax®-based

  6. Slide 6: Kentucky Manufacturing – Process & Capability

    Kentucky Manufacturing – Process & Capability ¹ Intended to illustrate maximum potential at full utilization of design capacity; assumes pricing of $3 per lb. Facility Targets: ~32.5 M LBS of Neat PHA ~65 M LBS Formulated PHA-Based Resin ~$190 M Revenue¹ 6 Continuous innovation effort reveals potent

  7. Slide 7: Q2 2023 Financial Summary

    Q2 2023 Financial Summary 2Q23 sales increase both sequentially and versus last year with strength in sales of PHA-based resins (up 69% sequentially and up 10% versus prior year) offset by lower funded R&D revenue as customers move to commercialization as well as a modest reduction in sales of PLA-b

  8. Slide 8: Guidance Summary

    1Q23 and 2Q23 results have been in-line with expectations Believe a bias toward lower end of Adj. EBITDA guidance range is prudent due to later than originally expected timing of large new program awards and increased disruption from Ukraine-Russia conflict on PLA product sales Remain confident in n

  9. Slide 9: tess, ~ e

    AN y . tess, ~ e Zé danimer \ oe soienutic. ‘y __ ABiotechnology Company

  10. Slide 10: EBITDA Reconciliation

    danimer scientific EBITDA Reconciliation A Biotechnology Company $ Thousands Net income (loss) ($39,241) ($30,445) Stock-based compensation 13,666 14,546 Interest, net 9,162 652 Depreciation and amortization 7,173 4,328 Remeasurement of private warrants (1,083) (2,012) Loss on extinguishment of debt

  11. Slide 11: Adjusted Gross Profit Reconciliation

    Adjusted Gross Profit Reconciliation 11

  12. Slide 12: Thank You

    a danimer ~ scientific THANK YOU

Danimer Scientific — Q2 2023 Earnings Presentation on 6ix